摘要
目的探讨血清前列腺特异性抗原(PSA)、游离前列腺特异性抗原(FPSA)、前列腺特异性抗原密度(PSAD)对经前列腺癌早期诊断的价值。方法对128例[其中确诊为前列腺癌32例,非前列腺癌患者中28例有前列腺上皮内瘤形成(PIN)]经直肠前列腺穿刺活检诊断的患者PSA、FPSA、FPSA/PSA比值、PSAD等计量资料以及分区域计数资料与病理诊断结果进行分析,探讨PSA、FPSA、FPSA/PSA、PSAD与前列腺癌的关系。结果前列腺癌和非前列腺癌患者PSA(P<0.001)和PSAD都存在显著差异(P<0.01),FPSA/PSA存在差异(P<0.05);将无前列腺癌及癌前病变、非前列腺癌存在PIN改变、前列腺癌患者分别作为第一、二、三组分组进行比较,第一、三组患者PSA(P<0.001)和PSAD存在显著差异(P<0.01),FPSA/PSA存在差异(P<0.05);第二、三组患者PSA(P<0.01)和PSAD都存在显著差异(P<0.01),FPSA/PSA无显著差异(P>0.05);第一、二组患者之间无显著差异。结论PSA是早期诊断前列腺癌的重要线索,结合FPSA/PSA比值对早期诊断前列腺癌有较大意义,PSAD可以作为前列腺癌早期诊断的辅助指标。
Objective To evaluate the value of serum prostate specific antigen （PSA）, free PSA （FPSA） and PSA density （PSAD） in early diagnosis of prostatic cancer. Methods Sixty-eight patients with benign prostate hyperplasia （BPH）, 28 with prostatic intraepithelial neoplasia （PIN） without canceration, and 32 with prostatic cancer, all diagnosed by prostatic biopsy, were enrolled in this study. Serum PSA and FPSA were measured and FPSA/PSA ratio and PSAD calculated for each patient, and the data analyzed to explore the association of these indices with prostatic cancer. Results Serum PSA level and PSAD were markedly different between the cancer patients and non-cancer patients （P〈0.001 and P〈0.01, respectively）. FPSA/PSA ratio also differed between them （P〈0.05）. The same results were also found between BPH and cancer patients. Significant difference was noted in serum PSA and PSAD between PIN and cancer patients （P〈0.01）, but not in FPSA/PSA ratio （P〉O.05）. No marked difference was observed in serum PSA, FPSA/PSA ratio and PSAD between BPH and PIN patients. Conclusion Serum PSA provides a very important clew for early diagnosis of prostatic cancer, and more accurate diagnosis can be obtained by considering also FPSA/PSA ratio. PSAD may also assist in the early diagnosis of prostatic cancer.
出处
《南方医科大学学报》
CAS
CSCD
北大核心
2007年第1期107-108,112,共3页
Journal of Southern Medical University
关键词
前列腺癌
早期诊断
前列腺特异性抗原
prostatic cancer
diagnosis
serum prostate specific antigen
